Logicworks Offers a Fast Track to Infrastructure-as-Code with Expanded Central Automation Platform
Jun 01, 2017 12:17 pm UTC| Business
NEW YORK, June 01, 2017 -- Logicworks, a leading cloud automation and managed services provider, today announced a new set of DevOps tools for running applications on the Amazon Web Services cloud. Based on customer...
TrackNet Adopts Semtech LoRa Technology for Tabs Home Monitoring Solution and Consumer IoT Systems
Jun 01, 2017 12:17 pm UTC| Business
SUNNYVALE, Calif., June 01, 2017 -- TrackNet, Inc., a cutting-edge LoRaWAN™ Internet of Things (IoT) solutions provider and developer of Tabs all-in-one monitoring solution, today announced a technology collaboration...
Logicworks Offers a Fast Track to Infrastructure-as-Code with Expanded Central Automation Platform
Jun 01, 2017 12:17 pm UTC| Business
NEW YORK, June 01, 2017 -- Logicworks, a leading cloud automation and managed services provider, today announced a new set of DevOps tools for running applications on the Amazon Web Services cloud. Based on customer...
Jun 01, 2017 12:15 pm UTC| Business
PLYMOUTH MEETING, Pa., June 01, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a clinical collaboration with Genentech, a member of the Roche Group, for advanced bladder cancer. The phase 1b/2...
Jun 01, 2017 12:15 pm UTC| Business
PLYMOUTH MEETING, Pa., June 01, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a clinical collaboration with Genentech, a member of the Roche Group, for advanced bladder cancer. The phase 1b/2...
Jun 01, 2017 12:15 pm UTC| Business
PLYMOUTH MEETING, Pa., June 01, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a clinical collaboration with Genentech, a member of the Roche Group, for advanced bladder cancer. The phase 1b/2...
Jun 01, 2017 12:15 pm UTC| Business
PLYMOUTH MEETING, Pa., June 01, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a clinical collaboration with Genentech, a member of the Roche Group, for advanced bladder cancer. The phase 1b/2...